Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers
Vous n'êtes pas connecté
Ovarian cancer is one of the most common malignancies in women worldwide. Unlike breast cancer, ovarian cancer lacks early diagnostic markers and does not show noticeable symptoms until cancer metastases, leading to a low survival rate for ovarian cancer patients.
Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers
Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers
Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer, with a low five-year survival rate of 13%. It is the third largest...
Breakthrough in triple-negative breast cancer diagnosis: New test improves early detection, offering better outcomes and personalized treatment...
Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative breast cancer patients.
Cleo Commences U.S. Clinical Trials Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to...
DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver...
Discover how Manuka honey's unique properties may slow breast cancer growth and enhance traditional treatments, offering new hope for patients.
Breast cancer is the leading cancer among Indian women, especially in urban regions due to lifestyle shifts. Early detection challenges contribute to...
Researchers at the National Institute of Biology are exploring new avenues for more effective treatment of glioblastoma, the most aggressive form of...